Company intelligence / Profile preview

Latigo Biotherapeutics

Thousand Oaks, California, United Stateslatigobio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Latigo Biotherapeutics has reported positive Phase 1 results for its lead candidate LTG‑001—an oral selective Nav1.8 inhibitor—for acute pain. The drug was well tolerated with rapid absorption and predictable pharmacokinetics in healthy volunteers. LTG‑305, another oral Nav1.8 inhibitor targeting chronic pain, entered Phase 1 trials in late 2024 with topline results expected mid‑2025. Both candidates aim to provide effective non-opioid alternatives for acute and chronic pain without addiction risk.

Therapeutic areas: Neurology
Modalities: Small molecules (oral selective Nav1.8 inhibitors)Ion channel modulators
Industry: Biotech

Drug pipeline

9 assets

LTG-001

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Latigo Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Latigo Biotherapeutics.

Explore the full profile